Dr. Khera highlights TRAVERSE trial of testosterone replacement therapy

In a video interview at the 24th Annual Fall Scientific Meeting of Sexual Medicine Society of North America in San Diego, California, Mohit Khera, MD, MBA, MPH, highlights key findings and future directions with the TRAVERSE trial (NCT03518034), assessing the safety of testosterone replacement therapy. Khera is a professor of urology at Baylor College of Medicine in Houston, Texas, and the current president of the SMSNA.

Video Transcript:

What were the notable findings from the TRAVERSE trial?

I am very excited to share the results of the TRAVERSE trial, the largest randomized placebo controlled trial ever published in men receiving testosterone. 5200 men receiving testosterone gel or placebo. What did it find? No increased risk in cardiovascular events in those men taking testosterone. We have several sub studies from the TRAVERSE trial. One is looking at sexual function. The study found that those men taking testosterone did not significantly improve erectile function, but it did significantly improve libido, which was sustainable all the way up to 2 years.

What are future directions with this work?

One of the benefits of the TRAVERSE trial were that many secondary and tertiary outcomes [were assessed], looking at anemia, bone mineral density, depression, diabetes, and those studies are yet to come. So far, we have only 2 published, which is the cardiovascular results, which showed no increase in cardiovascular events, and the sexual function results, showing improvements in libido, but not erectile function, in up to 2 years. But I'm very excited to look at the results coming out of the subsequent studies.

This transcription has been edited for clarity.